Palisade Bio: Phase 2/3 Ready Drug Candidate Entering Trials 2H 2021
May. 18, 2021
Palisade Bio (Nasdaq: PALI) is developing novel therapeutics designed to improve human health through therapeutic protection of the gastrointestinal (GI) mucosal barrier. PALI’s initial focus is combatting the interruption of GI function (ileus) following major surgery in order to accelerate recovery times and shorten the duration of patient hospital stays. Additionally, PALI believes that its investigational therapies have the potential to prevent the formation of post-surgical adhesions (reducing hospital re-admissions and additional surgeries), as well as to address health conditions and complications associated with disruption of the gastrointestinal mucosal barrier. Visit PALIinfo.com to learn more.
